Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $65 | $66 | $70 |
| % Growth | -99.3% | -1.1% | -6.4% | – |
| Cost of Goods Sold | $0 | $41 | $42 | $45 |
| Gross Profit | $0 | $24 | $24 | $26 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $18 | $18 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | -$1 |
| Operating Expenses | $0 | $18 | $19 | $18 |
| Operating Income | $0 | $5 | $5 | $8 |
| % Margin | 8% | 8% | 7% | 11.5% |
| Other Income/Exp. Net | $0 | -$1 | -$0 | $3 |
| Pre-Tax Income | $0 | $4 | $4 | $12 |
| Tax Expense | $0 | $1 | $0 | $3 |
| Net Income | $0 | $3 | $4 | $8 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS | 0.78 | 51.05 | 88.61 | 163.92 |
| % Growth | -98.5% | -42.4% | -45.9% | – |
| EPS Diluted | 0.78 | 51.05 | 88.61 | 163.92 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $5 | $5 | $5 |
| EBITDA | $0 | $10 | $11 | $12 |
| % Margin | 21.8% | 16% | 16.7% | 17.4% |